** Shares of drugmaker Axsome Therapeutics AXSM.O rise 13.5% to $119.99 premarket
** Co says it has entered into a settlement agreement with Teva Pharmaceuticals TEVA.TA, resolving all patent litigation related to AXSM's depression drug Auvelity
** Under terms of agreement, AXSM to grant Teva license to sell generic version of Auvelity beginning on or after March 31, 2039, if pediatric exclusivity is granted for Auvelity
** If no pediatric exclusivity is granted, AXSM to grant Teva license six months earlier - on or after September 30, 2038
** "This outcome is better than our base case, which assumed exclusivity through 2037"- brokerage Truist Securities
** Litigation resulted from regulatory submission by Teva to FDA seeking approval to market a generic version of Auvelity in the U.S. before expiration of applicable Axsome patents
** Stock had risen 6.3% in 2024
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。